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In 1976 Tony L. Yaksh and Thomas Rudy published a one-
and-half pages paper in Science entitled “Analgesia Medi-
ated by a Direct Spinal Action of Narcotics” [1]. This article 
opened two very important paths in pain medicine: it was 
understood that opioids can act on sites in the spinal cord, 
which had direct clinical applications, and that spinal 
effects of different classes of analgesics can be studied 
in a simple and practical model, using awake, behaving 
rodents with an intrathecal catheter implanted under 
anesthesia.
This happened 42  years ago. It is worth to remem-
ber that opioid receptors were demonstrated to exist in 
nervous tissue only 3  years earlier [2], and cloned two 
decades later [3]. Neuraxial – spinal and epidural – 
administration of opioids was rapidly accepted to clini-
cal use [4, 5]. Interestingly, the first documented case in 
whom morphine was administered intrathecally, with 
the local anesthetic cocaine, to treat pain is from 1901, 
see [6].
Hundreds and hundreds of studies on spinal effects of 
opioids and a plethora of other possible analgesics acting 
via different biochemical pathways have been published 
since the original publication in 1976 [1]. One of the advan-
tages of direct intrathecal administration of experimental 
compounds is that molecules, which would not reach the 
spinal cord receptors (e.g. some cannot cross the blood-
brain barrier, some are rapidly metabolised after oral or 
parenteral administration), such as small peptides can be 
used as research tools.
In the present issue of Scandinavian Journal of Pain, 
another report on effects of intrathecally administered 
opioids studied with the Yaksh-model, by the group of 
Tony L. Yaksh himself, is published [7]. In this paper, 
the potency and some adverse effects of a series of small 
opioid peptides (DALDA peptides: DMT-DALDA, dDALc, 
dDALcn, dDAL-TICP, and dDAL-TIPP) are characterised 
after intrathecal bolus administration in rats. Special 
emphasis is put into separating motor adverse effects 
from actual antinociceptive effects.
These peptides are hydrophilic, like morphine, 
which may make it possible that they could be used to 
produce long-lasting effect after single intrathecal bolus 
dose. As continuous intrathecal administration is some-
what problematic in clinical practice, especially after the 
adverse effects related to use of very thin spinal cathe-
ters that have led to market withdrawals, long analgesia 
after a single dose would be a highly desirable property 
of a new spinal analgesic. Obviously, before any clini-
cal application, more research on efficacy and safety is 
needed.
When the rats were treated with intrathecal morphine 
for 5 days before administration of DMT-DALDA, the anal-
gesic effect was not reduced [7], as it is for morphine itself 
as a result of development of tolerance. This “asymmet-
ric tolerance” is interesting, as it could possibly indicate 
that the peptide has better intrinsic effect compared with 
morphine.
For the Scandinavian Journal of Pain this paper opens 
another new area: the Journal has previously published 
few original papers on the preclinical or basic research on 
pain. It is nice to begin with a contribution of top class.
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